TriSalus Life Sciences Completes Exchange Offer and Consent Solicitation

TriSalus Life Sciences Inc., a pioneering oncology company focused on liver and pancreatic tumor treatment, has announced the completion of its previously declared exchange offer and consent solicitation related to its warrants. The company successfully issued 2,110,366 shares of its common stock in return for the tendered warrants.

Previously, the company and Continental Stock Transfer & Trust Company entered into a Warrant Amendment specifically focused on TriSalus' publicly-traded warrants. Additionally, the U.S. Securities and Exchange Commission (SEC) had declared effective the company's Registration Statement on Form S-4, which encompasses the shares of common stock issuable in the offer and as per the Warrant Amendment.

Oppenheimer & Co. Inc. was appointed as the Dealer Manager and Solicitation Agent for the exchange offer and consent solicitation. Morrow Sodali LLC served as the Information Agent, and Continental Stock Transfer & Trust Company acted as the Exchange Agent.

TriSalus Life Sciences is dedicated to revolutionizing cancer treatment through its advanced drug delivery technology aimed at improving therapeutic delivery to liver and pancreatic tumors. The company's platform features devices that employ a unique Pressure-Enabled Drug Delivery (PEDD) technology. This innovative approach is designed to address the anatomical challenges of arterial infusion in the pancreas, aiming to enhance therapeutic delivery to tumors while minimizing unwanted exposure to normal tissue.

The company's two FDA-cleared devices, the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors, encapsulate this PEDD approach. By modulating pressure and flow, these devices aim to improve patient outcomes by delivering more therapeutics directly to the tumor.

TriSalus is also advancing an investigational immunotherapy called nelitolimod. This candidate aims to tackle the immunosuppressive environment created by many tumors, which can limit the effectiveness of existing immunotherapies in treating liver and pancreatic cancers. Data derived from the company's Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials suggest that nelitolimod, when delivered via the PEDD approach, may have positive immune effects within the liver and throughout the body. Targeting TLR9, a receptor expressed across various cancer types, nelitolimod delivered by PEDD is set to be studied across multiple indications to address immune dysfunction and overcome drug delivery barriers in liver and pancreatic tumors.

Through collaborations with leading cancer centers nationwide and leveraging extensive expertise in immuno-oncology and innovative technology, TriSalus is dedicated to advancing medical innovations that significantly enhance patient outcomes.